Product Description
Mechanisms of Action: TGFR Inhibitor
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | European Medicines Agency | Germany | Hungary | Ireland | Italy | Lithuania | Portugal | Spain | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Stryker
Company Location: KALAMAZOO MI 49002
Company CEO: Kevin A. Lobo
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Eptotermin alfa](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Tibial Fractures|Other
Phase 3: Pain Unspecified
Phase 2: Femoral Fractures|Femoral Neck Fractures|Cleft Palate|Cleft Lip
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BMP7 | N/A |
Terminated |
Femur Head Necrosis |
2017-05-01 |
|
2006-006727-39 | P4 |
Completed |
Unknown |
2015-10-18 |
|
NCT00551941 | P4 |
Terminated |
Tibial Fractures |
2012-07-09 |
|
The use of BMP for alveolar reconstruction | P2 |
Terminated |
Cleft Lip|Cleft Palate |
2010-11-01 |